Chilblain lupus erythematosus and antiphospholipid antibody syndrome

Allegue, F.; Alonso, María Luisa Manzano; Rocamora, A.; Ledo, A.

doi:10.1016/s0190-9622(88)80377-3

Cited by 16 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some immunological anomalies are frequently observed (although not necessary for diagnosis) in CHLE, including hypergammaglobulinemia (>2/3 of patients), positive RF (∼50%), ANA, anti-Ro/SSA, and antiphospholipid (APL) antibodies [ 5 , 7 , 50 ]. Skin biopsy can be helpful in diagnosis (see below).…”

Section: Diagnosismentioning

confidence: 99%

Chilblains in immune-mediated inflammatory diseases: a review

et al. 2022

View full text Add to dashboard Cite

Chilblains were first described over a hundred years ago as cutaneous inflammatory lesions, typically on the digits, occurring on cold exposure. Chilblains can be primary, or secondary to a number of conditions such as infections, including COVID-19, and immune-mediated inflammatory disorders (IMIDs) with SLE being the commonest. Chilblain lupus erythematosus (CHLE) was first described in 1888 as cold-induced erythematous lesions before the terms ‘chilblains’ or ‘perniosis’ were coined. Diagnostic criteria exist for both chilblains and CHLE. Histopathologically, CHLE lesions show interface dermatitis with perivascular lymphocytic infiltrate. Immunofluorescence demonstrates linear deposits of immunoglobulins and complement in the dermo-epidermal junction. This narrative review focuses on chilblains secondary to immune-mediated inflammatory disorders, primarily the epidemiology, pathogenesis and treatment of CHLE.

show abstract

Section: Diagnosismentioning

confidence: 99%

Chilblains in immune-mediated inflammatory diseases: a review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All these features are well-known clinical associations of antiphospholipid antibodies'-', 7,8,11,14,29,30 Mayou et c~~.~' have reported a similar prevalence of anticardiolipin antibodies in patients with discoid lupus erythematosus, but the titers found by these authors were low and they were not associated with a thrombotic tendency.…”

Section: Resultsmentioning

confidence: 82%

Prevalence of Anticardiolipin Antibodies in Subacute Cutaneous Lupus Erythematosus

Fonseca

Alvarez

Gonzalez

et al. 1992

Lupus

View full text Add to dashboard Cite

We examined the prevalence of the antibodies to cardiolipin measured by solid-phase enzyme immunoassay during a prospective study of patients with subacute cutaneous lupus erythematosus (SCLE). Seven of 44 (16%) consecutive patients with SCLE had positive anticardiolipin antibodies; of these only three satisfied the American Rheumatism Association's revised criteria for the classification of systemic lupus erythematosus. Clinical findings probably associated with the positive anticardiolipin antibodies were found in four cases, including clotting abnormalities, thrombocytopenia, hemolytic anemia, livedo reticularis, chilblain lupus erythematosus lesions, migraine, leg venous thrombosis and pulmonary embolism after surgery, and spontaneous abortion. Our data suggest that it is reasonable to screen SCLE patients for these antibodies to confirm the presence of the antiphospholipid syndrome.

show abstract

“…Whereas the significance of a single low titer anticardiolipin antibody specimen is unknown, the antiphospholipid antibody syndrome, occurring alone or in conjunction with SLE, might explain both the chilblains and stroke in our patient. Chilblain lupus associated with lupus anticoagulant and anticardiolipin antibodies has been reported (6). Both of these antibodies have antiphospholipid activity and have been associated clinically with an increased frequency of thrombotic events (6,7).…”

Section: Discussionmentioning

confidence: 99%